Florian Klemm

Florian Klemm

Auto-generated profile, based on publicly available information

Florian Klemm

Department of Oncology, University of Lausanne, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
LALeila Akkari
Leila Akkari
RBRobert L. Bowman
Robert L. Bowman
JTJeremy Tessier
Jeremy Tessier
FKFlorian Klemm
Florian Klemm
SHShanna M. Handgraaf
Shanna M. Handgraaf
JJJohanna A. Joyce
Johanna A. Joyce
Macrophage subsets are dynamically altered during glioma response to radiotherapy, and their targeting delays tumor recurrence in preclinical trials.

18 October 2021 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
FKFlorian Klemm
Florian Klemm
AMAylin Möckl
Aylin Möckl
ASAnna Salamero-Boix
Anna Salamero-Boix
TATijna Alekseeva
Tijna Alekseeva
ASAlexander Schäffer
Alexander Schäffer
LSLisa Sevenich
Lisa Sevenich

26 June 2017 in Frontiers in Oncology
Verified
Journal Article
Open access
MBMichaela Bayerlová
Michaela Bayerlová
KMKerstin Menck
Kerstin Menck
FKFlorian Klemm
Florian Klemm
AWAlexander Wolff
Alexander Wolff
TPTobias Pukrop
Tobias Pukrop
ABAnnalen Bleckmann
Annalen Bleckmann
Breast cancer is a heterogeneous disease and has been classified into five molecular subtypes based on gene expression profiles. Signaling processes linked to different breast cancer molecular subtypes and different clinical outcomes are still poorly understood. Aberrant regulation of Wnt signaling has been implicated in breast cancer progression. In particular Ror1/2 receptors and several other members of the non-canonical Wnt signaling pathway were associated with aggressive breast cancer behavior. However, Wnt signals are mediated via multiple complex pathways and it is clinically important to determine which particular Wnt cascades, including their domains and targets, are deregulated in poor prognosis breast cancer. To investigate activation and outcome of the Ror2-dependent non-canonical Wnt signaling pathway we overexpressed the Ror2 receptor in MCF-7 and MDA-MB231 breast cancer cells, stimulated the cells with its ligand Wnt5a, and we knocked-down Ror1 in MDA-MB231 cells. We measured the invasive capacity of perturbed cells to assess phenotypic changes and mRNA was profiled to quantify gene expression changes. Differentially expressed genes were integrated into a literature-based non-canonical Wnt signaling network. The results were further used in the analysis of an independent dataset of breast cancer patients with metastasis-free survival annotation. Overexpression of the Ror2 receptor, stimulation with Wnt5a as well as the combination of both perturbations enhanced invasiveness of MCF-7 cells. The expression-responsive targets of Ror2 overexpression in MCF-7 induced a Ror2/Wnt module of the non-canonical Wnt signaling pathway. These targets alter regulation of other pathways involved in cell remodeling processing and cell metabolism. Furthermore, the genes of the Ror2/Wnt module were assessed as a gene signature in patient gene expression data and showed an association with clinical outcome. In summary, results of this study indicate a role of a newly defined Ror2/Wnt module in breast cancer progression and present a link between Ror2 expression and increased cell invasiveness.

30 August 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
RMRoeltje R. Maas
Roeltje R. Maas
KSKlara Soukup
Klara Soukup
FKFlorian Klemm
Florian Klemm
MKMara Kornete
Mara Kornete
RBRobert L. Bowman
Robert L. Bowman
JJJohanna A. Joyce
Johanna A. Joyce

7 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
FKFlorian Klemm
Florian Klemm
ASAlexander Schäffer
Alexander Schäffer
ASAnna Salamero-Boix
Anna Salamero-Boix
TATijna Alekseeva
Tijna Alekseeva
MSMichael Schulz
Michael Schulz
LSLisa Sevenich
Lisa Sevenich
SUMMARY: Tumor microenvironment-targeted therapies are emerging as promising treatment options for different cancer types. Tumor-associated macrophages and microglia (TAMs) represent an abundant non-malignant cell type in brain metastases and have been proposed to modulate metastatic colonization and outgrowth. We used an inhibitor of colony stimulating factor 1 receptor (CSF1R) to target TAMs at distinct stages of the metastatic cascade in preclinical breast-to-brain metastasis models and found that CSF1R inhibition leads to anti-tumor responses in prevention and intervention trials. However, in established brain metastases, compensatory CSF2Rb-STAT5-mediated pro-inflammatory TAM activation blunted the ultimate efficacy of CSF1R inhibition by inducing neuro-inflammation gene signatures in association with wound repair responses that fostered tumor recurrence. Consequently, combined blockade of CSF1R and STAT5 signaling led to sustained tumor control, a normalization of microglial activation states and amelioration of neuronal damage.

1 November 2025 in JCO Precision Oncology
Verified
Journal Article
Closed access
CPCloud P. Paweletz
Cloud P. Paweletz
TFThomas D. Forbes
Thomas D. Forbes
LYLaura Yee
Laura Yee
GHGrace Heavey
Grace Heavey
HHHua-Jun He
Hua-Jun He
CKChris Karlovich
Chris Karlovich
PURPOSE: We previously developed quality control materials (QCMs) to aid in the development of circulating tumor DNA (ctDNA) assays. In this study, we further characterize the performance of the QCMs relative to clinical samples. METHODS: QCMs were provided by three manufacturers. To functionally characterize the QCMs, we (1) evaluated EGFR L858R and ex19del (range, 0.5%-5.0% variant allele frequency [VAF]) in QCMs compared with clinical samples by droplet digital polymerase chain reaction (ddPCR), targeted-amplicon sequencing (Tag-seq), and hybrid capture next-generation sequencing (NGS); and (2) evaluated the QCMs and clinical samples near the Tag-seq limit of detection. A clinical pilot was also conducted in 11 clinical laboratories spanning four continents. RESULTS: For functional characterization, part 1, QCM VAFs for hybrid capture were similar to ddPCR for EGFR L858R but lower for ex19del. By contrast, hybrid capture results for EGFR L858R clinical samples showed a positive trend compared with ddPCR. For amplicon NGS, QCMs performed similarly to clinical samples for both variants. For part 2, observed hit rates approximated expected values. In the clinical pilot, median ex19del VAF was higher for Tag-seq than hybrid capture for both 1.0% and 0.5% QCM formulations. Median QCM L858R VAFs were similar for Tag-seq and hybrid capture, with greatest interlaboratory differences observed for Thermo Fisher Scientific QCMs. For non- EGFR variants, we observed assay and QCM-dependent trends, with no particular QCM or assay driving these trends. CONCLUSION: This project revealed unexpected differences in performance of both assays and QCMs. These findings highlight the need for further validation across diverse alteration types and merit consideration by laboratories that rely on QCMs to develop and perform ctDNA assays for diagnostic applications.